Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income of -CN¥47.23M in Q4 FY2025

Q4 FY2025 net income was -CN¥47.23M.

Context

  • Net income amounted to 71.3% of revenue in FY2025, up 64.1 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥47.23M+96.3% QoQ
Last fiscal yearDec 2025
-CN¥82.97M-715.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-715.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Income history

CNY · from the cash flow

Latest · FY2025
(82.97M) CNY
Year-over-year change
-715.9%

Net Income vs competitors

How ZYBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -715.9% is the lowest of 9, against a peer median of +7.2%.
  • Net income amounts to 71.3% of revenue for ZYBT, versus a peer median of 2293.7%.
ZYBT Competitors
Net Income for ZYBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRZNSurrozen, Inc.LTM Mar 2026$342.56M USD+319.3%+88.7%4571.1%
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥82.97M CNY-715.9%—71.3%
TILInstil Bio, Inc.LTM Mar 2026$47.38M USD-39.3%-31.6%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$36.38M CAD+1.7%+3.0%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$35.52M CAD+12.8%+16.7%—
SERASera Prognostics, Inc.LTM Mar 2026$32.14M USD-2.6%-10.3%56386.0%
PDEXPro-Dex, Inc.LTM Mar 2026$12M USD+28.1%+25.2%16.1%
EXOZeXoZymes, Inc.LTM Mar 2026$9.67M USD+44.2%+87.2%—
APYXApyx Medical CorporationLTM Mar 2026$9.05M USD-55.1%-21.9%16.2%
Peer median (excluding ZYBT) —+7.2%+9.9%2293.7%

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income46.47M55.74M37.51M13.47M(82.97M)
Depreciation & Amortization16.01M18.8M23.91M24.16M25.96M
Deferred Income Tax(358K)(1.09M)758K924K11.1M
Stock-Based Compensation00000
Change in Working Capital(33.71M)(66.82M)(20.49M)(977K)44.83M
Accounts Receivables(40.91M)(47.38M)38.05M11.31M61.41M
Inventory(12.34M)(12.33M)(12.9M)(5.88M)6.25M
Accounts Payables17.63M(9.67M)(35.61M)(404K)(3.36M)
Other Working Capital1.91M2.56M(10.03M)(6M)(19.47M)
Other Non-Cash Items3.4M10.7M6.5M3.47M14.42M
Operating Cash Flow31.81M17.34M48.18M41.05M13.33M
Capital Expenditures(26.4M)(27.33M)(11.6M)(27.77M)(12.63M)
Acquisitions (Net)00000
Purchases of Investments00(1.22M)00
Sales of Investments00000
Other Investing Activities(7.21M)0(3.15M)(14.08M)(11.62M)
Investing Cash Flow(26.27M)(27.33M)(11.77M)(27.67M)(12.63M)
Debt Repayment8M34.88M24.97M(2.74M)(12.09M)
Common Stock Issued000043.08M
Common Stock Repurchased00000
Dividends Paid(11.05M)(21.43M)(39.45M)(16.02M)0
Other Financing Activities0(1)(4.5M)(3.37M)1.32M
Financing Cash Flow(3.05M)13.46M(18.98M)(22.13M)32.31M
Effect of Forex Changes000168K(1.29M)
Net Change in Cash2.49M3.46M17.44M(8.58M)31.73M
Free Cash Flow5.41M(9.99M)36.58M13.27M703K

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.